matrix-m2
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2012 (NCT01667341)
Timeline
Indications
Mechanism of action
- UnclearImmunity, active
Unclear immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- matrix-m2
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03146403 | Phase 2 | May 24, 2017 | Genocea Biosciences, Inc. |
| NCT02515175 | Phase 2 | Nov 1, 2015 | Genocea Biosciences, Inc. |
| NCT02300142 | Phase 2 | Jan 1, 2015 | Genocea Biosciences, Inc. |
| NCT02114060 | Phase 2 | Jul 1, 2014 | Genocea Biosciences, Inc. |
| NCT01667341 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2012 | Genocea Biosciences, Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Genocea Biosciences, Inc. | For profit | 5 | 5 | 1 | 2012 |
1 organizations
Page 1 / 1